7.32
                                            
                                Panoramica
                                Notizia
                                Cronologia dei prezzi
                                    Catena di opzioni
                                Financials
                                    Perché BCRX Giù?
                                Forum
                                Previsione
                        
                        Precedente Chiudi:
              $7.25
            Aprire:
              $7.28
            Volume 24 ore:
                5.72M
            Relative Volume:
              1.35
            Capitalizzazione di mercato:
                $1.54B
            Reddito:
              $557.51M
            Utile/perdita netta:
              $-35.71M
            Rapporto P/E:
              -40.67
            EPS:
                -0.18
            Flusso di cassa netto:
                $15.50M
            1 W Prestazione:
              +1.67%
            1M Prestazione:
              -3.56%
            6M Prestazione:
                -17.29%
            1 anno Prestazione:
              -8.61%
            Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Nome
                  
                      Biocryst Pharmaceuticals Inc
                    
                Settore
                  Telefono
                  
                      919-859-1302
                    
                Indirizzo
                  
                      4505 EMPEROR BOULEVARD, DURHAM, NC
                    
                Confronta BCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS | 
|---|---|---|---|---|---|---|
|   
                          
                                BCRX
                            
                             Biocryst Pharmaceuticals Inc | 7.32 | 1.53B | 557.51M | -35.71M | 15.50M | -0.18 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 | 
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione | 
|---|---|---|---|
| 2025-10-15 | Ripresa | TD Cowen | Buy | 
| 2025-10-01 | Downgrade | Evercore ISI | Outperform → In-line | 
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight | 
| 2025-02-25 | Iniziato | Wedbush | Outperform | 
| 2023-11-20 | Ripresa | JP Morgan | Overweight | 
| 2023-09-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform | 
| 2023-08-04 | Aggiornamento | Jefferies | Hold → Buy | 
| 2023-07-13 | Aggiornamento | BofA Securities | Neutral → Buy | 
| 2023-02-22 | Aggiornamento | Needham | Hold → Buy | 
| 2022-11-02 | Aggiornamento | Evercore ISI | In-line → Outperform | 
| 2022-08-05 | Downgrade | Evercore ISI | Outperform → In-line | 
| 2022-08-05 | Downgrade | Oppenheimer | Outperform → Perform | 
| 2022-04-18 | Downgrade | Barclays | Overweight → Equal Weight | 
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral | 
| 2021-12-10 | Iniziato | Oppenheimer | Outperform | 
| 2021-08-06 | Downgrade | Jefferies | Buy → Hold | 
| 2021-08-03 | Iniziato | Cantor Fitzgerald | Overweight | 
| 2021-03-01 | Iniziato | Cowen | Outperform | 
| 2020-09-29 | Ripresa | JP Morgan | Overweight | 
| 2020-06-17 | Iniziato | BTIG Research | Neutral | 
| 2020-05-05 | Aggiornamento | Barclays | Equal Weight → Overweight | 
| 2019-11-15 | Aggiornamento | BofA/Merrill | Neutral → Buy | 
| 2019-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform | 
| 2018-11-16 | Ripresa | Piper Jaffray | Overweight | 
| 2018-08-08 | Ripresa | JP Morgan | Overweight | 
| 2018-07-17 | Aggiornamento | BofA/Merrill | Underperform → Neutral | 
| 2018-06-22 | Iniziato | Seaport Global Securities | Neutral | 
| 2018-01-02 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform | 
| 2017-12-20 | Iniziato | Barclays | Equal Weight | 
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform | 
| 2017-09-06 | Aggiornamento | JP Morgan | Neutral → Overweight | 
| 2017-09-06 | Aggiornamento | Jefferies | Hold → Buy | 
| 2017-02-16 | Iniziato | Ladenburg Thalmann | Buy | 
| 2016-08-12 | Aggiornamento | Piper Jaffray | Neutral → Overweight | 
| 2016-08-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform | 
| 2016-02-09 | Reiterato | FBR Capital | Outperform | 
| 2016-02-09 | Downgrade | JP Morgan | Overweight → Neutral | 
| 2016-02-09 | Downgrade | Needham | Buy → Hold | 
                    Mostra tutto
                     
                  
                Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
Will BioCryst Pharmaceuticals Inc. stock maintain growth storyGlobal Markets & Reliable Intraday Trade Plans - newser.com
What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackEarnings Miss & Daily Profit Focused Stock Screening - newser.com
Is BioCryst Pharmaceuticals Inc. stock bottoming out2025 Momentum Check & Smart Swing Trading Techniques - newser.com
Is BioCryst Pharmaceuticals Inc. stock ready for a breakoutEarnings Risk Summary & Real-Time Price Movement Reports - newser.com
Why retail investors pile into BioCryst Pharmaceuticals Inc. stock2025 Short Interest & Verified Technical Signals - newser.com
Will BioCryst Pharmaceuticals Inc. stock attract ESG investorsMarket Sentiment Summary & Fast Exit/Entry Strategy Plans - newser.com
Why BioCryst Pharmaceuticals Inc. stock could benefit from AI revolutionWeekly Stock Recap & Reliable Intraday Trade Alerts - newser.com
# BioCryst’s SWOT analysis: stock positioned for growth amid HAE market expansion - Investing.com
BioCryst Pharmaceuticals (BCRX) Price Target Increased by 19.59% to 21.51 - Nasdaq
BioCryst Pharmaceuticals Inc.’s volatility index tracking explainedJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com
Why BioCryst Shares Plunged - AOL.com
Aug Shorts: Why hedge funds are buying BioCryst Pharmaceuticals Inc. stockTrade Entry Report & Weekly Stock Performance Updates - Fundação Cultural do Pará
When is the best time to exit BioCryst Pharmaceuticals Inc.July 2025 Snapshot & Free Low Drawdown Momentum Trade Ideas - newser.com
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? - sharewise.com
Will BioCryst Pharmaceuticals Inc. stock outperform international peersPortfolio Update Report & AI Optimized Trading Strategy Guides - Fundação Cultural do Pará
BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Monday - MarketBeat
Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biocryst Pharmaceuticals Inc Azioni (BCRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale | 
|---|---|---|---|---|---|---|---|
| HEGGIE THERESA | Director | Aug 13 '25 | Sale | 8.51 | 70,000 | 595,868 | 65,352 | 
        Apri su Yahoo
        |
        Apri su Google
            |
            Aperto in Finviz
        |
        Apri in MarketWatch
            |
            Aperto a EDGAR    
        |
        Aperto su Reuters
    
    
                Capitalizzazione:
                 
                  | 
                Volume (24 ore):
                 
            
         
                     
                             Scarica l'app Stockscreener
                    Scarica l'app Stockscreener